CDK4 and chordoma: The tumor evolution detected in this case demonstrated that, chordoma patients whose tumors harbor potentially sensitizing alterations to G1/S cell-cycle signaling pathway may benefit from CDK4/6 inhibitor, and also implies necessity of combination therapies because of the possibility of drug-resistance generated by single drug administration.